On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Pfizer receives additional orders for its COVID-19 treatment, after US requests more doses, and several Chinese companies are also reported to have begun selling the product.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Millstone Medical Outsourcing is keeping up the pace of its deal-driven expansion strategy by closing the takeover of regulatory testing services provider Ethide Laboratories.
Emergent’s application for its Narcan product to be sold OTC for the treatment of opioid overdose has been accepted by the US FDA and provided priority review.
CordenPharma joins global science initiative SBTi and announces commitment to ambitious reduction in greenhouse gas emissions in alignment with the Paris agreement.
The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.
ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseases.
First ever longtudinal study from ALS non-profit focuses on finding digital biomarkers using IBM Research’s proprietary AI. The study leverages audiovisual samples from participants with ALS, genetic carriers, and caregivers.
For its two lead oncology programs, the company will pursue “market-based pricing”, moving away from plans to “dramatically lower prices” for treatments.
The two companies will combine real-world datasets to better understand marketing treatment with Bristol Myers Squibb’s drug in a post-marketing setting.
Icon is looking to its Accellacare global clinical research network to mitigate the effect of site staffing issues on the speed at which trials are executed and revenues are realized.
In-home nurse visits, using familiar mobile devices to upload health data, and telemedicine calls with a doctor are the elements of decentralized clinical trials with the biggest positive impact on participation in future studies, according to a survey.
CVS Health and Walgreens announce that they will settle all opioid claims against them by US states, while it is reported that Walmart will do the same.
The long-running case relates to the change of formulation to its Levothyrox product, specifically the information the company provided when the product was altered.
CPhI Frankfurt takes place next week: covering the full supply chain from research and manufacturing to packaging and finished products. Here’s five ideas on how to make the most of the event.
A federal judge in the Southern District of Florida has sentenced two Florida women to prison for their part in a conspiracy to falsify clinical trial data.
According to the agency, Teva communicated that it would have difficulties supplying immediate release formulations of the drug due to manufacturing delays.
The regulatory agencies of six European countries are now actively prompting clinical trials sponsors to publicly report their clinical trial results—and have the power to issue fines of up to €250,000 ($243,000) for noncompliance.
The company announces further measures against a counterfeiting network it accused of being responsible for selling illegitimate Gilead HIV medications.
